INTRODUCTION:

The landscape of modern pharmaceutical research has undergone a profound transformation, driven by the relentless pursuit of innovative drug delivery systems. The quest to improve therapeutic outcomes, minimize side effects, and enhance patient compliance has spurred scientists and researchers to explore novel approaches to drug administration.

In this dynamic landscape, proniosomes have emerged as a promising and versatile platform that bridges the advantages of niosomes and liposomes while overcoming their respective limitations¹. This convergence has opened up exciting possibilities for revolutionizing drug delivery in the pharmaceutical industry. Proniosomes represent a captivating and promising avenue in drug delivery due to their unique capabilities. Their capacity to enhance drug stability, prolong drug release, improve bioavailability, and enable targeted delivery positions them as a versatile solution to the challenges faced in conventional drug therapies. By harnessing the power of nanotechnology in proniosome development, researchers can venture into new frontiers of personalized and more effective drug treatments. This aligns well with the ever-evolving demands of modern medicine and the vision for precision healthcare. The potential of proniosomes has ignited significant interest and ongoing research in the pharmaceutical field. As nanotechnology continues to advance, proniosomes hold the promise of becoming an indispensable tool in tailoring drug delivery to individual patient needs. By offering a sophisticated and adaptable approach, proniosomes present an attractive alternative to conventional drug delivery systems. In this context, this review article aims to provide a comprehensive analysis of the recent advancements in proniosomes and their applications in harnessing nanotechnology for enhanced drug delivery². By exploring the principles of proniosome preparation, formulation optimization, and excipient selection, as well as the diverse characterization techniques, this review article seeks to elucidate the progress made in this rapidly evolving field. Furthermore, it delves into the various applications of proniosomes in drug delivery, encompassing oral, topical, transdermal, ocular, pulmonary, and targeted delivery routes.

PRINCIPLES OF PRONIOSOME PREPARATION:

Proniosomes represent a unique and promising approach to drug delivery, combining the benefits of niosomes and liposomes in a dry, free-flowing formulation. The successful preparation of proniosomes relies on several fundamental principles, encompassing the selection of appropriate excipients, formulation techniques, and methods to ensure stability and efficacy³. In this section, we explore the key principles underlying the preparation of proniosomes.

a) Choice of Lipids and Surfactants: The foundation of proniosome formulation lies in selecting suitable lipids and surfactants that can self-assemble into stable vesicles upon hydration. The choice of lipids is crucial to determine the physicochemical properties of the proniosomes, such as size, bilayer thickness, and fluidity, which ultimately impact drug encapsulation and release kinetics. Additionally, surfactants play a vital role in stabilizing the proniosomal structure and preventing aggregation during storage and rehydration⁴.

b) Hydration Techniques: Proniosomes are usually presented as dry, powdered forms that require hydration before administration. Various hydration techniques, such as simple agitation, sonication, or vortexing, can be employed to convert the proniosomal powders into niosomal dispersions. The method chosen should ensure uniform hydration and dispersion of the vesicles to guarantee consistent drug delivery performance⁵.

c) Stabilization Strategies: The stability of proniosomes is critical for their successful implementation as drug delivery carriers. Techniques to enhance proniosome stability, such as freeze-drying, lyophilization, or the incorporation of stabilizing agents, must be carefully considered during the preparation process. Stability is particularly vital for long-term storage and transportation, preserving the integrity of the proniosomal structure and drug payload⁶.

d) Drug Loading and Encapsulation: Efficient drug loading into proniosomes is essential to achieve therapeutic drug concentrations and optimal drug release profiles. The drug loading process should be optimized to maximize drug encapsulation while minimizing leakage or premature release. Factors influencing drug encapsulation include drug lipophilicity, vesicle composition, and the method of drug incorporation ⁴.

e) Characterization Techniques: Thorough characterization of proniosomes is essential to assess their quality and performance. Various techniques, such as microscopy (e.g., electron microscopy, optical microscopy), dynamic light scattering, zeta potential measurements, and differential scanning calorimetry, are employed to evaluate the size distribution, surface charge, and physical stability of proniosomal vesicles⁴.

Researchers can produce well-defined and stable proniosomes with tailored properties by adhering to the above principles, enabling the development of effective drug delivery systems. Understanding the principles of proniosome preparation is fundamental in designing formulations with enhanced drug release profiles, improved bioavailability, and potential for targeted delivery to specific tissues or cells. The continual exploration and refinement of these principles will undoubtedly contribute to the advancement of proniosomes as a promising and versatile platform in the field of pharmaceutical research and drug delivery. The formation of proniosomes is shown in the Figure 1

Figure 1. Schematic Representation of Proniosome Formation and Drug Release Mechanism.

FORMULATION OPTIMIZATION AND EXCIPIENT SELECTION:

The successful development of proniosomes as a robust drug delivery system relies on meticulous formulation optimization and judicious selection of excipients. Fine-tuning the composition of proniosomes is essential to achieve desirable characteristics such as enhanced stability, prolonged drug release, and improved bioavailability. In this section, we delve into the critical aspects of formulation optimization and the strategic selection of excipients in proniosome development.

a) Excipient Functions and Roles: Excipients play multifaceted roles in proniosome formulations. They not only act as stabilizers to prevent vesicle aggregation and fusion but also contribute to the maintenance of vesicle integrity during storage and reconstitution. Moreover, excipients can influence drug encapsulation efficiency, drug release kinetics, and the biocompatibility of proniosomes⁷.

b) Lipid Composition and Ratios: The selection of appropriate lipids and their ratios is pivotal in determining the physicochemical properties of proniosomes. Different lipids offer distinct advantages, such as improved membrane fluidity, increased drug solubility, or enhanced vesicle stability. By adjusting lipid ratios, researchers can tailor the proniosomal vesicles' size, lamellarity, and drug-loading capacity⁷.

c) Surfactant Selection: Surfactants play a crucial role in proniosome preparation by aiding the formation of stable vesicles and preventing aggregation. The choice of surfactant influences proniosome stability, size distribution, and membrane permeability. Selecting surfactants compatible with both lipids and the drug of interest is essential to ensure efficient drug encapsulation and sustained release⁸.

d) Hydration Medium: The medium used to reconstitute proniosomes after their dry presentation can significantly impact their stability and drug release kinetics. Different hydration media, such as water, buffer solutions, or biological fluids, may affect vesicle formation and drug release profiles. The selection of an appropriate hydration medium should consider the intended route of administration and the physiological environment at the site of drug delivery⁸.

e) Incorporation of Additives: Incorporating additives into proniosome formulations can further enhance their performance. For instance, the addition of antioxidants can help protect the drug from degradation, while pH modifiers can control drug release at specific sites within the body. Additives like penetration enhancers may facilitate drug transport across biological barriers, particularly for transdermal or ocular applications⁸.

f) Optimization Techniques: Formulation optimization often involves the use of experimental design approaches, such as factorial designs or response surface methodologies. These techniques allow researchers to systematically vary formulation factors and assess their impact on proniosome characteristics. Optimization studies can yield formulations with improved drug encapsulation efficiency, prolonged release, and enhanced stability⁸.

A carefully designed formulation can lead to pronounced improvements in drug delivery performance, unlocking the full potential of proniosomes as a versatile and effective platform for therapeutic interventions. Continuous refinement in these areas will undoubtedly contribute to the successful translation of proniosomes from the laboratory to clinical applications, further advancing the field of modern drug delivery.

CHARACTERIZATION TECHNIQUES FOR PRONIOSOMES:

Characterization of proniosomes is a crucial step in assessing their quality, stability, and drug delivery potential. Various analytical techniques are employed to evaluate the physicochemical properties, morphology, and drug-loading characteristics of proniosomal formulations⁹. In this section, we explore the key characterization techniques used to gain insights into the behavior and performance of proniosomes.

a) Microscopy:

Microscopy techniques, such as optical microscopy, transmission electron microscopy (TEM), and scanning electron microscopy (SEM), provide valuable information about the morphology and size distribution of proniosomes. Optical microscopy offers a quick assessment of vesicle formation, while TEM and SEM allow researchers to visualize the internal and surface characteristics of proniosomal vesicles at the nanoscale.

b) Particle Size Analysis:

Dynamic light scattering (DLS) and laser diffraction are common techniques used to measure the particle size distribution of proniosomes. Particle size is a critical parameter that affects drug encapsulation, stability, and in vivo behavior. Accurate particle size analysis enables researchers to optimize formulation parameters for specific drug delivery applications¹⁰.

c) Zeta Potential Measurements:

Zeta potential measurements are employed to evaluate the surface charge of proniosomal vesicles. Zeta potential influences vesicle stability and colloidal behavior. By assessing the zeta potential, researchers can gain insights into the stability and interaction of proniosomes with biological environments¹⁰.

d) Differential Scanning Calorimetry (DSC):

DSC is a thermal analysis technique used to investigate the thermal behavior and phase transitions of proniosomal formulations. DSC helps identify the presence of different lipid phases, assess lipid-drug interactions, and determine the thermal stability of proniosomes¹⁰.

e) Fourier Transform Infrared Spectroscopy (FTIR):

FTIR spectroscopy is employed to study the interactions between lipids, surfactants, and drugs in proniosomal formulations. FTIR spectra provide information about molecular vibrations, aiding in the characterization of chemical bonds and potential drug-excipient interactions ¹¹.

f) Drug Encapsulation Efficiency:

Quantifying the drug encapsulation efficiency is essential to assess the proniosomes' ability to encapsulate and protect the drug payload. High encapsulation efficiency ensures optimal drug delivery and reduces the risk of drug leakage during storage or administration ¹¹.

g) In vitro Drug Release Studies:

In vitro drug release studies are conducted to assess the drug release kinetics from proniosomes under simulated physiological conditions. These studies provide valuable information about the release profile, release mechanism, and sustained drug release potential of proniosomal formulations ^12,13.

h) Stability Studies:

Stability studies are crucial to evaluate the long-term stability and shelf-life of proniosomes. Accelerated stability studies conducted under various storage conditions help assess proniosome formulation robustness and potential changes in physicochemical properties over time¹².

ADVANCEMENTS IN NANOTECHNOLOGY FOR PRONIOSOMES:

Nanotechnology has revolutionized the field of drug delivery, and its application in proniosomes has opened new frontiers for enhanced therapeutic outcomes. The integration of nanotechnology into proniosome formulations has led to remarkable advancements, addressing challenges in drug delivery and improving the overall performance of proniosomes ¹⁴. In this section, we explore the cutting-edge advancements in nanotechnology that have propelled proniosomes as a promising and versatile drug delivery platform.

1. Nanoscale Lipid Assemblies:

Nanotechnology enables the precise engineering of lipid assemblies at the nanoscale. By manipulating lipid compositions and employing novel lipid-based materials, researchers can create proniosomes with controlled size, lamellarity, and drug-loading capabilities. These nanoscale lipid assemblies offer enhanced stability and efficient drug encapsulation, promising more targeted and sustained drug release¹⁴.

2. Surface Modifications for Targeted Delivery:

Nanotechnology allows for surface modifications of proniosomes with ligands, antibodies, or peptides, enabling targeted drug delivery. These functionalized proniosomes can recognize specific receptors or biomarkers on target cells, enhancing drug accumulation at the site of action while reducing off-target effects. This targeted approach enhances the therapeutic efficacy of drugs, particularly in the treatment of cancer and other diseases with localized pathologies ¹³.

3. Encapsulation of Hydrophilic and Hydrophobic Drugs:

Nanotechnology facilitates the simultaneous encapsulation of hydrophilic and hydrophobic drugs within proniosomes. Co-encapsulation of diverse drug types expands the therapeutic possibilities, allowing combination therapies and synergistic effects. This versatility is particularly beneficial for complex disease conditions requiring multiple drugs to achieve optimal therapeutic outcomes ¹⁵.

4. Triggered and Controlled Drug Release:

Nanotechnology enables the design of stimuli-responsive proniosomes that respond to specific triggers, such as changes in pH, temperature, or enzymatic activity. These smart proniosomes can release the drug payload at the target site, in response to the disease microenvironment, or in a controlled manner over an extended period. Triggered drug release enhances drug efficacy, reduces side effects, and improves patient compliance ¹⁶.

5. Nanoscale Penetration Enhancers:

Nanotechnology has facilitated the development of nanoscale penetration enhancers that can be incorporated into proniosomes to improve drug permeation across biological barriers. These enhancers can open tight junctions or transiently disrupt cell membranes, enhancing drug transport and absorption at specific sites of administration, such as the skin or mucosal surfaces ¹⁷.

6. Long Circulating Nanoparticles:

By employing nanotechnology, proniosomes can be engineered to possess long circulating properties. PEGylation, the attachment of polyethylene glycol chains to the proniosomal surface, imparts stealth properties, reducing recognition and clearance by the reticuloendothelial system. This extended circulation time increases drug bioavailability and allows for less frequent dosing ^17,18.

7. Combination with Other Nanocarriers:

Nanotechnology facilitates the integration of proniosomes with other nanocarriers, such as polymeric nanoparticles or liposomes, creating hybrid delivery systems. These combinations capitalize on the unique strengths of each carrier, offering enhanced drug-loading capacity, improved stability, and controlled release properties⁵.

The advancements in nanotechnology have transformed proniosomes into sophisticated drug delivery systems with superior capabilities for targeted therapy, prolonged drug release, and improved patient outcomes. These nanotechnological breakthroughs hold great promise for personalized medicine and precision drug delivery, heralding a new era of pharmaceutical research and clinical applications. As the field of nanotechnology continues to progress, further innovations in proniosome development are anticipated, further solidifying their position as a cutting-edge drug delivery platform. A comparative description of proniosomes with other nanocarriers is provided in the Table 1.

APPLICATIONS OF PRONIOSOMES IN DRUG DELIVERY:

Proniosomes have demonstrated immense potential across diverse drug delivery routes, owing to their unique properties and versatility as carriers. In this section, we explore the wide-ranging applications of proniosomes in drug delivery, highlighting their effectiveness and adaptability in various administration routes.

a) Oral Drug Delivery:

Oral drug delivery remains the most common and preferred route of administration for many pharmaceuticals. Proniosomes offer several advantages in oral drug delivery, such as improved drug stability, enhanced bioavailability, and controlled release. Once ingested, proniosomes disintegrate into niosomes in the gastrointestinal tract, facilitating drug absorption and protection against degradation. The flexibility of proniosomes in encapsulating both hydrophilic and hydrophobic drugs makes them an ideal choice for oral delivery of a wide range of therapeutic agents¹⁹.

b) Topical Drug Delivery:

Proniosomes have found promising applications in topical drug delivery, catering to dermatological and cosmetic formulations. Proniosomal gels, creams, and lotions enhance drug permeation through the skin, enabling localized and targeted drug delivery. Their non-greasy and elegant formulation offers improved patient compliance and convenience. Additionally, nanotechnology advancements allow for the incorporation of penetration enhancers, enabling better drug transport across the skin barrier¹¹.

c) Transdermal Drug Delivery:

Transdermal drug delivery via proniosomes holds immense potential for systemic drug administration with controlled release profiles. Proniosomal patches or gels deliver drugs across the skin, bypassing first-pass metabolism and achieving prolonged systemic effects. Their ability to encapsulate both hydrophilic and hydrophobic drugs makes proniosomes an attractive option for transdermal delivery of a wide range of therapeutics⁷.

d) Ocular Drug Delivery:

Proniosomes offer significant advantages in ocular drug delivery due to their ability to improve drug solubility, enhance corneal penetration, and sustain drug release. Proniosomal formulations, such as eye drops or ophthalmic gels, ensure prolonged contact time and targeted drug delivery to the ocular tissues. The potential to incorporate surface-modified proniosomes facilitates targeted delivery to specific ocular sites, offering new avenues for treating ocular diseases effectively⁴.

e) Pulmonary Drug Delivery:

Proniosomes have emerged as promising carriers for pulmonary drug delivery, offering a solution to challenges associated with traditional inhalation systems. Proniosomes deliver drugs to the lungs, ensuring improved drug deposition and reducing the risk of drug degradation in the harsh lung environment. The capability to encapsulate a wide range of drugs, including peptides and proteins, expands the therapeutic possibilities for respiratory diseases¹⁴.

f) Targeted Drug Delivery:

The ability to modify the surface of proniosomes has opened up exciting opportunities for targeted drug delivery. Surface functionalization with ligands or antibodies allows proniosomes to selectively bind to specific cell receptors or tissues, leading to enhanced drug accumulation at the target site and reduced systemic side effects. This targeted approach shows promise in the treatment of cancers, infectious diseases, and other conditions where localized drug delivery is crucial¹⁴.

SAFETY AND BIOCOMPATIBILITY CONSIDERATIONS:

Ensuring the safety and biocompatibility of proniosomes is of paramount importance for their successful translation into clinical applications. As novel drug delivery carriers, proniosomes undergo rigorous evaluations to assess their potential for adverse effects and interactions with biological systems. In this section, we explore the key safety and biocompatibility considerations associated with proniosomes.

a) Cytotoxicity Studies:

Cytotoxicity studies are essential to evaluate the impact of proniosomes on cellular viability. These studies are typically performed on various cell lines, representing different tissues or organs that may come into contact with the proniosomes during drug delivery. By assessing cell viability, researchers can gauge the potential cytotoxic effects of proniosomes and ensure their safety for use²⁰.

b) Hemocompatibility Assessment:

Hemocompatibility studies evaluate the interaction of proniosomes with blood components. These studies are crucial, especially for intravenous or systemic drug delivery routes, where proniosomes may encounter blood cells and proteins. Evaluating the impact on red blood cells, platelets, and clotting factors helps ensure that proniosomes do not cause hemolysis or trigger adverse reactions within the circulatory system²¹.

c) Irritation and Sensitization Testing:

For topical and transdermal applications, irritation and sensitization testing are conducted to assess the potential for skin irritation or allergic reactions upon proniosome contact. These tests help identify any adverse skin reactions, ensuring that proniosomes are safe for use in topical formulations¹².

d) Acute and Subacute Toxicity Studies:

Acute and subacute toxicity studies involve administering proniosomal formulations to animal models over a short and extended period, respectively. These studies help determine the dose at which proniosomes may exhibit toxic effects and identify any organ-specific toxicity. The data from these studies are essential for establishing safe dosing regimens and identifying potential target organs for further evaluation ¹³.

e) Biodegradation and Biocompatibility:

Biodegradation studies investigate the fate of proniosomes upon administration and the biocompatibility of degradation products. Proniosomes designed to degrade into biocompatible components are preferable to minimize long-term accumulation and potential adverse effects¹⁵.

f) Immune Response Evaluation:

Evaluating the immunological response induced by proniosomes is crucial to understanding their immunogenicity and potential for eliciting immune reactions. The modulation of the immune response by proniosomes can impact their therapeutic efficacy and long-term use^22,23.

g) In vivo Pharmacokinetics and Biodistribution:

In vivo pharmacokinetics and biodistribution studies provide insights into the fate of proniosomes after administration, their circulation time, tissue distribution, and clearance. Understanding how proniosomes interact with the body and are eliminated is essential for optimizing drug delivery performance and minimizing any accumulation in non-target tissues¹³.

SCALE-UP AND COMMERCIALIZATION PROSPECTS:

As proniosomes continue to show promise as an innovative drug delivery platform, considerations for scale-up and commercialization become crucial steps in their development process. Scaling up proniosome production from laboratory to industrial levels requires careful planning, optimization, and adherence to regulatory guidelines. In this section, we explore the challenges and opportunities associated with scaling up proniosome production and their commercialization prospects.

1. Manufacturing Process Optimization:

Scaling up proniosome production involves optimizing the manufacturing process to ensure reproducibility, consistency, and cost-effectiveness. Factors such as equipment selection, formulation parameters, and process validation are carefully evaluated to achieve large-scale production without compromising product quality²⁴.

2. Quality Control and Assurance:

Maintaining stringent quality control and assurance measures is imperative during scale-up. Robust quality control protocols must be established to monitor critical quality attributes, such as particle size, drug encapsulation efficiency, and stability. Implementing good manufacturing practices (GMP) is essential to comply with regulatory requirements and ensure product safety and efficacy²⁵.

3. Stability Studies:

Long-term stability studies are vital for assessing the shelf life and performance of proniosomes under various storage conditions. Stability data generated during scale-up provides crucial information for establishing product expiration dates and storage recommendation²⁶.

4. Cost Optimization:

Scalability should be balanced with cost-effectiveness to ensure competitive pricing in the market. Assessing raw material costs, production efficiencies, and economies of scale is essential to offer proniosomal formulations at affordable prices while maintaining profit margins²⁷.

5. Regulatory Considerations:

Navigating the regulatory landscape is a critical aspect of commercializing proniosomes. Complying with regional and international regulations, such as those set by the Food and Drug Administration (FDA) in the United States or the European Medicines Agency (EMA) in Europe, is essential to gain approval for commercial distribution ²⁸.

6. Intellectual Property Protection:

Protecting intellectual property is essential for securing a competitive advantage in the market. Patents, trademarks, and trade secrets should be carefully managed to safeguard the unique formulation and production methods of proniosomal products ²⁹.

7. Market Penetration and Targeted Marketing:

Developing a comprehensive market penetration strategy is essential for the successful commercialization of proniosomes. Identifying key target markets, understanding customer needs, and strategically marketing the unique benefits of proniosomes will help create a strong market presence ²⁰.

8. Collaboration and Partnerships:

Collaborating with pharmaceutical companies, contract manufacturers, or research institutions can facilitate scale-up and expedite commercialization efforts. Partnerships may provide access to specialized expertise, resources, and distribution channels, accelerating the transition from research to market¹⁰.

9. Lifecycle Management:

Considering the dynamic nature of the pharmaceutical industry, lifecycle management is vital for the sustained success of proniosomal products. Ongoing research and development efforts should focus on product improvements, line extensions, and exploring new therapeutic applications to meet evolving market demands ¹⁴. The summary of in vivo pharmacokinetics and biodistribution data for proniosomes is provided in Table 2.

CONCLUSION:

Proniosomes, a cutting-edge drug delivery platform harnessing the power of nanotechnology, hold immense promise in revolutionizing pharmaceutical therapies. These represent a revolutionary advancement in drug delivery, offering tailored solutions to improve therapeutic outcomes and patient experiences. The potential of proniosomes to overcome biological barriers, provide targeted drug delivery, and enhance treatment efficacy holds great promise for diverse therapeutic applications. As researchers and manufacturers continue to explore and refine this innovative platform, proniosomes are expected to emerge as a transformative force in the pharmaceutical industry, delivering personalized and effective therapies to patients worldwide.

CONFLICT OF INTEREST:

The authors declare no conflicts of interest.

ACKNOWLEDGMENTS:

The authors would like to thank Ms. M. Vinny Therissa, Assistant Professor, Aditya College of Pharmacy for her kind support during the preparation of this work.

REFERENCES:

1. Jangam RP, Thombre AN, Gaikwad NP. A Review: Proniosomes as a Novel Drug Delivery System. Asian Jour Pharm and Technol. 2017; 7(3): 166. doi: 10.5958/2231-5713.2017.00027.7

2. Srikanth, Kumar YA, Setty CM. Formulation and Evaluation of Maltodextrin Based Doxorubicin HCl Proniosomes. Rese Jour of Pharm and Technol. 2019; 12(6): 2776. doi: 10.5958/0974-360X.2019.00466.9

3. Arvapalli S, Anka Rao A. Preparation, Characterization and Optimization of Maltodextrin based Efavirenz loaded Proniosomes using Box Behnken Design: In vitro and ex-vivo permeation study. Research Journal of Pharmacy and Technology. 2023: 669-75. doi: 10.52711/0974-360X.2023.00114

4. Srikanth K, Nappinnai M, Gupta VRM. Proniosomes: A novel drug carrier system. Research Journal of Pharmacy and Technology. 2010; 3(3): 709-11.

5. Ahmad W, Khan T, Basit I, Imran J. A Comprehensive Review on Targeted Drug Delivery System. AJPR. 2022:335-40. doi: 10.52711/2231-5691.2022.00053

6. Devi GC, Kumar AE. Microbubbles-A Potential Novel Targeted Drug Delivery. Research Journal of Pharmacy and Technology. 2019; 12(5): 2511-6. doi: 10.5958/0974-360X.2019.00423.2

7. Ajrin M, Anjum F. Proniosome: A Promising Approach for Vesicular Drug Delivery. Turk J Pharm Sci. 2022; 19(4): 462-75. doi: 10.4274/tjps.galenos.2021.53533

8. Pagar KR, Khandbahale SV. A Review on Novel Drug Delivery System: A Recent Trend. Asian Jour Pharm and Technol. 2019; 9(2): 135. doi: 10.5958/2231-5713.2019.00023.0

9. Praveen K, Balamurugan K. Targeted Drug Delivery through Nanosponges and its Approach. Rese Jour of Pharm and Technol. 2020; 13(7): 3524. doi: 10.5958/0974-360X.2020.00624.1

10. Blazek-Welsh AI, Rhodes DG. Maltodextrin-based proniosomes. AAPS Pharm Sci. 2001;3(1):1-8. doi: 10.1208/ps030101

11. El Maghraby GM, Ahmed AA, Osman MA. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm J. 2015; 23(1): 67-74. doi: 10.1016/j.jsps.2014.05.001

12. Ibrahim MMA, Sammour OA, Hammad MA, Megrab NA. In Vitro Evaluation of Proniosomes as a Drug Carrier for Flurbiprofen. AAPS Pharm Sci Tech. 2008;9(3):782-90. doi: 10.1208/s12249-008-9114-0

13. Nasr M. In Vitro and In Vivo Evaluation of Proniosomes Containing Celecoxib for Oral Administration. AAPS PharmSciTech 2010;11(1):85-9. doi: 10.1208/s12249-009-9364-5

14. Khatoon M, Shah KU, Din FU, Shah SU, Rehman AU, Dilawar N, et al. Proniosomes derived niosomes: recent advancements in drug delivery and targeting. Drug Deliv. 24(2):56-69. doi: 10.1080/10717544.2017.1384520

15. Radha GV, Rani TS, Sarvani B. A review on proniosomal drug delivery system for targeted drug action. J Basic Clin Pharm. 2013; 4(2): 42-8. doi: 10.4103/0976-0105.113609

16. Shah H, Nair AB, Shah J, Bharadia P, Al-Dhubiab BE. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats. DARU Journal of Pharmaceutical Sciences. 2019; 27(1): 59-70. doi: 10.1007/s40199-019-00242-x

17. Shehata TM, Ibrahim MM, Elsewedy HS. Curcumin Niosomes Prepared from Proniosomal Gels: In Vitro Skin Permeability, Kinetic and In Vivo Studies. Polymers (Basel). 2021; 13(5): 791. doi: 10.3390/polym13050791

18. Shehata TM, Abdallah MH, Ibrahim MM. Proniosomal Oral Tablets for Controlled Delivery and Enhanced Pharmacokinetic Properties of Acemetacin. AAPS Pharm Sci Tech. 2014; 16(2): 375-83. doi: 10.1208/s12249-014-0233-5

19. Sahu K, Pathak R, Agrawal N, Banjare P, Sharma H, Sahu G. A Review of the Novel Drug Delivery System used in the Treatment of Cancer. Rese Jour Pharmaceut Dosag Form and Technol. 2019; 11(3): 199. doi: 10.5958/0975-4377.2019.00035.1

20. Emad Eldeeb A, Salah S, Ghorab M. Proniosomal gel-derived niosomes: an approach to sustain and improve the ocular delivery of brimonidine tartrate; formulation, in-vitro characterization, and in-vivo pharmacodynamic study. Drug Deliv. 2019; 26(1): 509-21. doi: 10.1080/10717544.2019.1609622

21. Abu El-Enin ASM, Khalifa MKA, Dawaba AM, Dawaba HM. Proniosomal gel-mediated topical delivery of fluconazole: Development, in vitro characterization, and microbiological evaluation. J Adv Pharm Technol Res. 2019; 10(1): 20-6. doi: 10.4103/japtr.JAPTR_332_18

22. Solanki N, Prajapati S. Self emulsifying drug delivery system (SEDDS): a review. International Journal of Pharmaceutical Research and Bio-science. 2012; 1.

23. Solanki AB, Parikh JR, Parikh RH. Formulation and optimization of piroxicam proniosomes by 3-factor, 3-level box-behnken design. AAPS Pharm Sci Tech. 2007; 8(4): 43. doi: 10.1208/pt0804086

24. Teaima MH, Yasser M, El-Nabarawi MA, Helal DA. Proniosomal Telmisartan Tablets: Formulation, in vitro Evaluation and in vivo Comparative Pharmacokinetic Study in Rabbits. Drug Des Devel Ther. 2020; 14: 1319-31. doi: 10.2147/DDDT.S245013

25. Rajabalaya R, Leen G, Chellian J, Chakravarthi S, David SR. Tolterodine Tartrate Proniosomal Gel Transdermal Delivery for Overactive Bladder. Pharmaceutics. 2016; 8(3): 27. doi: 10.3390/pharmaceutics8030027

26. Pinzaru I, Tanase A, Enatescu V, Coricovac D, Bociort F, Marcovici I, et al. Proniosomal Gel for Topical Delivery of Rutin: Preparation, Physicochemical Characterization and In Vitro Toxicological Profile Using 3D Reconstructed Human Epidermis Tissue and 2D Cells. Antioxidants (Basel). 2021; 10(1): 85. doi: 10.3390/antiox10010085

27. Gharbavi M, Amani J, Kheiri-Manjili H, Danafar H, Sharafi A. Niosome: A Promising Nanocarrier for Natural Drug Delivery through Blood-Brain Barrier. Adv Pharmacol Sci. 2018; 2018: 6847971. doi: 10.1155/2018/6847971

28. Ge X, Wei M, He S, Yuan WE. Advances of Non-Ionic Surfactant Vesicles (Niosomes) and Their Application in Drug Delivery. Pharmaceutics. 2019; 11(2): 55. doi: 10.3390/pharmaceutics11020055

29. Fathi-Azarbayjani A, Ng KX, Chan YW, Chan SY. Lipid Vesicles for the Skin Delivery of Diclofenac: Cerosomes vs. Other Lipid Suspensions. Adv Pharm Bull. 2015; 5(1): 25-33. doi: 10.5681/apb.2015.004

Received on 07.08.2023 Modified on 06.03.2024

Asian J. Res. Pharm. Sci. 2024; 14(3):279-286.

DOI: 10.52711/2231-5659.2024.00046

Nanocarrier Property	Proniosomes	Liposomes	Polymeric Nanoparticles	Solid Lipid Nanoparticles
Drug Encapsulation Efficiency	High	High	Variable, depends on polymer and drug	High
Stability	Improved	Prone to aggregation	Moderate to High	Prone to crystallization
Drug Release Profiles	Controlled and sustained	Can be modified	Depends on polymer and drug	Controlled and sustained
Targeted Delivery Capabilities	Feasible with Surface Modification	Achievable with Ligands	Can be Modified	Achievable with Ligands
Size Distribution	Adjustable	Limited Range	Adjustable	Limited Range
Flexibility in Drug Loading	High	Limited	Moderate to High	High
Biocompatibility	Generally High	Generally High	Generally High	Generally High
Scale-up and Production Ease	Favorable	Established Processes	Varies by Polymer	Established Processes

Administration Route	Proniosome Formulation	Circulation Time	Tissue Distribution	Elimination Kinetics
Oral	Proniosome Capsules	Extended	Targeted to Gastrointestinal Tract	Hepatic Metabolism
Topical	Proniosome Gel	Localized	Skin and Underlying Tissues	Metabolized and Excreted in Urine
Transdermal	Proniosome Patch	Prolonged	Systemic Absorption	Renal Excretion
Ocular	Proniosome Eye Drops	Moderate	Targeted to Ocular Tissues	Lacrimal Clearance
Pulmonary	Proniosome Aerosol	Extended	Lung Tissue	Pulmonary Excretion
Targeted Delivery	Ligand-Modified Proniosomes	Variable	Targeted to Specific Cells or Tissues	Clearance via RES